News
Public · Published
Palantir Technologies 3Q 2026: Revenue $2.31B, EPS $0.44— 10-Q Summary
Palantir reported third-quarter 2026 revenue of $2.31 billion, up 95.9% from a year earlier. Net income attributable to common stockholders rose 137.2% to $1.13 billion, and diluted earnings per share increased to $0.44 from $0.18. Commercial and government revenue also grew sharply.
Published:
Updated:
What happened
Palantir reported third-quarter 2026 revenue of $2.31 billion, up 95.9% from a year earlier. Net income attributable to common stockholders rose 137.2% to $1.13 billion, and diluted earnings per share increased to $0.44 from $0.18. Commercial and government revenue also grew sharply.
Confirmed
Global impact / market context
The reported growth suggests rising demand across both commercial and government customers, while more customers and higher revenue from top accounts could support future sales. If broader access to Palantir’s platform accelerates as the company expects, it may require investment in delivery and support, affecting costs and profit per sale.
Analyst inference
The results show growth in both business lines rather than reliance on only commercial or government revenue. However, the supplied figures do not describe cash available, spending needs, or future guidance, so investors cannot assess from this summary alone how much growth converts into lasting earnings.
Analyst inference
What to watch
- Watch whether upcoming reported periods sustain commercial and government revenue growth; slower expansion in either line could weaken the growth picture conveyed by this quarter. Analyst inference
- Track customer count and revenue from the largest accounts, since continued increases could support sales while dependence on a few customers could make results less predictable. Analyst inference
- The company expects broader platform access across commercial and government markets to accelerate; watch for later disclosures showing whether that expectation translates into deployments and revenue. Confirmed
Evidence
- Original source link unavailable